TEVA withdraws $40 billion hostile take-over bid against Mylan

TEVA announced on July 27th its intention to withdraw its unsolicited expression of interest to acquire rival Mylan N.V., a leading global pharmaceutical company with a growing portfolio of around 1,400 generic pharmaceuticals and brand medications.
A CRA team led by Raphaël De Coninck and including Elina Koustoumpardi, Roman Fischer, Mikaël Hervé, Nitika Bagaria, Guillaume Débarbat, and Ilia Karmanov provided economic support to Mylan in its antitrust defense in front of the European Commission against the attempted hostile take-over.

Related Capabilities